EACS Guidelines
Advanced Search…
  • Log in
  • Home
  • Contents
    • Summary of Changes from v.11.0 to v.11.1
    • Abbreviations
    • Version Information
  • Assessment
  • ART
    • Readiness to Start/Maintain ART
    • Initiation of ART: No Prior ART Exposure
    • Initial Regimens: ART-naïve Adults
    • Primary HIV Infection (PHI)
    • Switch Strategies
    • Virological Failure
    • Pregnancy and HIV
    • ART: TB/HIV Co-infection
    • Post-exposure Prophylaxis (PEP)
    • Pre-exposure Prophylaxis (PrEP)
    • ARV Adverse Effects & Drug Classes
  • DDIs & Prescribing Issues
    • DDIs, Prescribing, Overview
    • Drug-drug interactions
      • Analgesics & ARVs
      • Anti-coagulants/Antiplatelet Agents & ARVs
      • Anti-depressants & ARVs
      • Anti-hypertensives & ARVs
      • Anti-malarial Drugs & ARVs
      • Anti-tuberculosis drugs & ARVs
      • Anxiolytics & ARVs
      • ARVs & non-ARVs
      • Bronchodilators & ARVs
      • Contraceptives & ARVs
      • Corticosteroids & ARVs
      • COVID-19 Therapies & ARVs
      • Hormone Replacement Therapy (HRT) & ARVs
      • Immunosuppressants & ARVs
      • Pulmonary Anti-hypertensives & ARVs
      • Viral Hepatitis Drugs & ARVs
    • Other prescribing issues
      • ARVs: Swallowing Difficulties
      • ARV Dosing: Hepatic Impairment
      • ARV Dosing: Renal Impairment
      • Non-ARV Drug Dosing: Renal Insufficiency
      • Prescribing in Older Persons with HIV
      • Drug Classes To Avoid in Older Persons with HIV
      • Hormone Therapy: Gender Transitioning
  • Co-morbidities
    • Co-morbidities, Overview
    • Opioid Addiction, Pharmacological Treatment
    • Cancer
      • Cancer: Screening Methods
      • Cancer: Treatment Monitoring
    • Lifestyle Interventions
    • Cardiovascular Disease
      • Prevention of Cardiovascular Disease (CVD)
      • Hypertension: Diagnosis, Grading & Management
      • Hypertension: Drug Sequencing Management
      • DDIs: Anti-hypertensives & ARVs
    • Type 2 Diabetes
    • Dyslipidemia
      • Dyslipidaemia
      • Treatment Goals for LDL-c for Very High and High CVD Risk Persons
    • Bone Disease
      • Bone Disease
      • Vitamin D Deficiency
      • Fracture Reduction
    • Kidney disease
      • Kidney Disease: Definition, Diagnosis and Management
      • ARV-associated Nephrotoxicity
      • Proximal Renal Tubulopathy (PRT)
      • ARV dosing: renal impairment
    • Liver Disease
      • Increased ALT/AST: Work-up & Management
      • Liver Cirrhosis: Classification, Surveillance
      • Liver Cirrhosis: Management
      • Non-Alcoholic Fatty Liver Disease (NAFLD)
      • Hepatorenal Syndrome /Acute Kidney Injury (HRS-AKI)
      • ARV Dosing: Hepatic Impairment
    • Lipodystrophy and Obesity:
    • Hyperlactataemia and Lactic Acidosis
    • Travel
      • Travel
      • DDI: Antimalarial Drugs & ARVs
    • Vaccination
    • Sexual, Reproductive Health
      • Sexual and Reproductive Health
      • Sexual Dysfunction
      • Treatment of Sexual Dysfunction in PLWH
    • Mental Health in PLWH: Depression & Anxiety Disorders
      • Depression: Screening, Diagnosis and Management
      • Antidepressants
      • DDI: Antidepressants and ARVs
      • Anxiety Disorders: Screening and Diagnosis
      • Anxiety Disorders: Management
      • Classification, Doses and Adverse Effects of Anxiolytics
      • DDI: Anxiolytics & ARVs
    • Cognitive Impairment
    • Chronic Lung Disease
      • Chronic Lung Disease
      • DDI: Bronchodilators & ARVs
      • DDI: Pulmonary Antihypertensives & ARVs
    • Managing Older Persons with HIV
    • Frailty
    • Falls
    • Solid Organ Transplant (SOT)
      • Solid Organ Transplantation (SOT)
      • DDI: Immunosuppressants & ARVs
  • HIV/Hep Co-infection
    • Clinical Management and Treatment of Viral Hepatitis Co-infections
    • Treatment and Monitoring of Persons with HBV/HIV Co-infection
    • HCV/HIV Co-infection
      • Treatment and Monitoring of Persons with HCV/HIV Co-infection
      • HCV Treatment Options
      • DDIs: HCV DAAs & ARVs
      • Recently Acquired HCV Infection
    • Tests: Fibrosis / Cirrhosis
    • Hepatitis D and E infection
  • Opportunistic Infections, COVID-19
    • Opportunistic Infections and COVID-19, Overview
    • Immune Reconstitution Inflammatory Syndrome (IRIS)
    • Primary Prophylaxis of OIs
    • Bacillary Angiomatosis
    • Candidiasis
    • Cryptococcosis
    • Cryptosporidiosis
    • Cystoisosporiasis
    • Cytomegalovirus (CMV)
    • Herpes Simplex Virus (HSV)
    • Histoplasmosis
    • Leishmaniasis
    • Non-Tuberculous Mycobacteria (NTM)
    • Pneumocystis jirovecii Pneumonia (PcP)
    • Progressive Multifocal Leukoencephalopathy (PML)
    • Talaromycosis
    • Toxoplasma gondii Encephalitis
    • Tuberculosis
    • Varicella Zoster Virus (VZV)
    • Management of COVID-19 in persons with HIV
  • Paediatric HIV Treatment
    • ART: Initiation and Initial Regimen
    • ART: Preferred & Alternative First Line Options, Formulations, Dosing
    • Switch Strategies, Special Populations
    • Adherence, Virological Failure and Second Line ART
  • Video links
  • References
    • References, Overview
    • Assessment of Initial & Subsequent Visits, References
    • ARV Treatment, References
    • DDIs & Other Prescribing Issues, References
    • Co-morbidities Prevention & Management, References
    • Chronic Viral Hepatitis Co-infections, References
    • Opportunistic Infections and COVID-19, References
    • Paediatric HIV Treatment References
  • 2021 Images
    • Tablet_11.jpg
    • Tablet_11.jpg
    • DDI Images 2021
      • DDI after Oral and Intramuscular Administration of CAB and RPV 2021
      • DDI between ARVs and Non-ARVs 2021
      • DDI between Analgesics and ARVs 2021
      • DDI between Anticoagulants/Antiplatelet Agents and ARVs 2021
      • DDI between Antidepressants and ARVs 2021
      • DDI between Antihypertensives and ARVs 2021
      • DDI between Antimalarial Drugs and ARVs 2021
      • DDI between Anti-tuberculosis Drugs and ARVs 2021
      • DDI between Anxiolytics and ARVs 2021
      • DDI between Bronchodilators (for COPD) and ARVs 2021
      • DDI between Contraceptives and ARVs
      • DDI between Corticosteroids and ARVs 2021
      • DDI between COVID-19 Therapies and ARVs 2021
      • DDI between Hormone Replacement Therapy (HRT) and ARVs 2021
      • DDI between Immunosuppressants (for SOT) and ARVs 2021
      • DDI between Pulmonary Antihypertensives and ARVs 2021
      • DDI between Viral Hepatitis Drugs and ARVs 2021
      • (B) DDI between Hormone Replacement Therapy (HRT) and ARVs 2021 (B)
      • (C) DDI between Hormone Replacement Therapy (HRT) and ARVs 2021
      • DDI between Hormone Replacement Therapy (HRT) and ARVs 2021(New)
      • Mechanisms of Drug-Drug Interactions with Antiretroviral Drugs (App only) 2021
      • Common DDI w/ ARV Drugs 2021
    • Table Images 2021
      • Swallowing Difficulties1 2021
      • Swallowing Difficulties 2 2021
      • Dose Adjustment of ARVs for Impaired Hepatic Function 2021
      • Dose Adjustment of ARVs for Impaired Renal Function 2021
      • Classification, Doses and Adverse Effects of Anxiolytics 2021
    • Algorithm Images 2021
      • Prescribing in Older PLWH 2021
      • Smoking Cessation 2021
      • Prevention of CVD 2021
      • Management of PLWH w/ Increased ALT/AST 2021
      • Hypertension: Diagnosis, Grading, and Management 2021
      • Hypertension: Drug Sequencing Management 2021
      • Type 2 Diabetes: Management 2021
      • Treatment Goals for LDL-c for Very High and High CVD Risk Persons 2021
      • Kidney Disease: Definition, Diagnosis and Management 2021
      • Algorithm for surveillance for varices and primary prophylaxis 2021
      • Non-Alcoholic Fatty Liver Disease (NAFLD) Flow Chart Algorithm 2021
      • Algorithm for Diagnosis and Management of Cognitive Impairment in PLWH without Obvious Confounding Conditions 2021
      • Management of Recently Acquired HCV Infection in PLWH 2021
      • Chronic Lung Disease Management Algorithm 2021
      • Treatment of COPD Algorithm 2021
      • Algorithm Recommended for Frailty Screening 2021
      • Screening for Falls Algorithm 2021
You are here:
  1. Home
  2. 2021 Images
  3. Tablet_11.jpg
Tablet_11.jpg https://eacs.sanfordguide.com/2021-images/tablet_11-1.jpg/view https://eacs.sanfordguide.com/2021-images/tablet_11-1.jpg/@@download/image/Tablet_11.jpg

Tablet_11.jpg

Tablet_11.jpg
Click to view full-size image… Size: 228.5 KB
© EACS - All Rights Reserved | Privacy Policy